Equities analysts expect Medpace Holdings Inc (NASDAQ:MEDP) to report earnings of $0.63 per share for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Medpace’s earnings, with estimates ranging from $0.59 to $0.65. Medpace posted earnings of $0.40 per share during the same quarter last year, which would indicate a positive year over year growth rate of 57.5%. The business is scheduled to report its next earnings report after the market closes on Monday, October 29th.
According to Zacks, analysts expect that Medpace will report full year earnings of $2.44 per share for the current year, with EPS estimates ranging from $2.36 to $2.48. For the next year, analysts anticipate that the firm will post earnings of $2.85 per share, with EPS estimates ranging from $2.74 to $2.93. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Medpace.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Tuesday, July 31st. The company reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.19. The company had revenue of $117.80 million during the quarter, compared to the consensus estimate of $104.97 million. Medpace had a net margin of 10.44% and a return on equity of 14.22%. The firm’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 earnings per share.
MEDP has been the subject of several analyst reports. BidaskClub raised shares of Medpace from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 12th. William Blair raised shares of Medpace from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 31st. SunTrust Banks initiated coverage on shares of Medpace in a research report on Monday, September 17th. They set a “hold” rating and a $63.00 price target for the company. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research report on Friday, August 10th. Finally, Credit Suisse Group raised their price target on shares of Medpace from $42.00 to $49.00 and gave the company an “outperform” rating in a research report on Tuesday, July 31st. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company. Medpace presently has an average rating of “Buy” and a consensus price target of $46.57.
In other Medpace news, major shareholder Medpace Investors, Llc sold 2,713 shares of Medpace stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $58.47, for a total value of $158,629.11. Following the completion of the sale, the insider now owns 9,027,814 shares of the company’s stock, valued at approximately $527,856,284.58. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 731,460 shares of Medpace stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $59.26, for a total transaction of $43,346,319.60. Following the completion of the sale, the chief executive officer now directly owns 849,621 shares of the company’s stock, valued at approximately $50,348,540.46. The disclosure for this sale can be found here. Insiders have sold 11,907,218 shares of company stock valued at $656,554,339 in the last three months. 29.50% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in Medpace in the 2nd quarter worth approximately $107,000. Atria Investments LLC bought a new stake in Medpace in the 3rd quarter worth approximately $246,000. Metropolitan Life Insurance Co. NY grew its position in Medpace by 57.1% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 4,144 shares of the company’s stock worth $178,000 after purchasing an additional 1,507 shares during the period. Sei Investments Co. grew its position in Medpace by 5,087.5% in the 2nd quarter. Sei Investments Co. now owns 4,565 shares of the company’s stock worth $196,000 after purchasing an additional 4,477 shares during the period. Finally, CAPROCK Group Inc. bought a new stake in Medpace in the 2nd quarter worth approximately $223,000. 39.29% of the stock is owned by institutional investors and hedge funds.
Shares of MEDP traded down $1.13 on Friday, hitting $52.45. 229,367 shares of the stock traded hands, compared to its average volume of 533,229. The company has a market capitalization of $1.91 billion, a P/E ratio of 34.51, a price-to-earnings-growth ratio of 1.37 and a beta of 1.02. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.32. Medpace has a one year low of $31.70 and a one year high of $65.09.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
See Also: Return on Equity (ROE)
Get a free copy of the Zacks research report on Medpace (MEDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.